{"analyses":[{"ciLowerLimit":"1.00","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.47","groupDescription":"Day 4","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0464","paramType":"Odds Ratio (OR)","paramValue":"1.21","statisticalMethod":"Proportional Odds Model"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.1","upperLimit":"6.1","value":"4.6"},{"groupId":"OG001","lowerLimit":"3.6","upperLimit":"6.8","value":"5.2"}]}],"title":"Day 4 NIAID-OS 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"2.4","value":"1.5"},{"groupId":"OG001","lowerLimit":"0.6","upperLimit":"2.4","value":"1.5"}]}],"title":"Day 4 NIAID-OS 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2","upperLimit":"1.4","value":"0.8"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.7","value":"0.3"}]}],"title":"Day 4 NIAID-OS 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.6","upperLimit":"22.3","value":"19.4"},{"groupId":"OG001","lowerLimit":"20.6","upperLimit":"26.7","value":"23.6"}]}],"title":"Day 4 NIAID-OS 4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.5","upperLimit":"44.5","value":"41.0"},{"groupId":"OG001","lowerLimit":"35.5","upperLimit":"42.5","value":"39.0"}]}],"title":"Day 4 NIAID-OS 5"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.5","upperLimit":"25.4","value":"22.4"},{"groupId":"OG001","lowerLimit":"18.9","upperLimit":"24.8","value":"21.8"}]}],"title":"Day 4 NIAID-OS 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.8","upperLimit":"10.9","value":"8.9"},{"groupId":"OG001","lowerLimit":"6.2","upperLimit":"10.1","value":"8.1"}]}],"title":"Day 4 NIAID-OS 7"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"2.2","value":"1.4"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.9","value":"0.4"}]}],"title":"Day 4 NIAID-OS 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"756"},{"groupId":"OG001","value":"762"}],"units":"Participants"}],"description":"Overall improvement on the National Institute of Allergy and Infectious Diseases ordinal scale:\n\n1\\. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized, requiring supplemental oxygen; 6.Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on invasive mechanical ventilation or ECMO; 8. Death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Placebo administered orally QD with standard of care.","id":"OG000","title":"Placebo + SOC"},{"description":"4 mg baricitinib administered orally QD with standard of care.","id":"OG001","title":"Baricitinib + SOC"}],"paramType":"NUMBER","populationDescription":"All participants randomly assigned to study intervention. Participants with missing baseline ordinal scale were excluded.","reportingStatus":"POSTED","timeFrame":"Day 4","title":"Percentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 4","type":"SECONDARY","unitOfMeasure":"percentage of participants"}